Format
Items per page
Sort by

Send to:

Choose Destination

Links from GEO DataSets

Items: 20

1.
Full record GDS5420

Psoriasis response to brodalumab: dose response and time course

Analysis of non-lesional and lesional psoriatic skins for up to 43 days following treatment with various doses of brodalumab, a human IgG2 mAb that selectively binds and blocks signaling through IL-17RA. Results provide insight into the molecular effect of blocking IL-17 signaling in psoriatic skin.
Organism:
Homo sapiens
Type:
Expression profiling by array, count, 3 agent, 4 dose, 25 individual, 4 time, 2 tissue sets
Platform:
GPL570
Series:
GSE53552
99 Samples
Download data: CEL
DataSet
Accession:
GDS5420
ID:
5420
2.

Gene expression profiling in psoriatic lesional and non-lesional skin [brodalumab treatment]

(Submitter supplied) To explore the psoriasis phenotype and pathways involved in psoriasis, we characterized gene expression in lesional and non-lesional skin from psoriasis patients. Furthermore, we explored the effects of various doses of brodalumab on lesional skin over time.
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS5420
Platform:
GPL570
99 Samples
Download data: CEL
Series
Accession:
GSE53552
ID:
200053552
3.

Lesional and non-lesional skin gene-expression profiles from Phase-3 clinical trials of Brodalumab

(Submitter supplied) IL-17 antagonists induce impressive clinical benefit in psoriasis, but it is unknown too what extent cellular and molecular characteristics of psoriasis are suppressed by a clinically relevant dose and schedule of any IL-17 antagonist. Examine the effects the IL-17A receptor antagonist brodalumab, on the clinical and molecular characteristics of psoriasis, including IL-17 dependent gene-sets.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
565 Samples
Download data: CEL
Series
Accession:
GSE117468
ID:
200117468
4.

Effective treatment of psoriasis with etanercept is linked to suppression of IL17 signaling, not immediate response TNF

(Submitter supplied) The success of TNF inhibitors for treatment of psoriasis and other inflammatory diseases was previously attributed to blockade of innate immunity. In a clinical trial using etanercept TNF blocking agent to treat psoriasis vulgaris, we used affymetrix gene arrays to analyze broad gene profiles in lesional skin at multiple timepoints during drug treatment (baseline, and weeks 1, 2, 4 and 12) compared to non-lesional skin. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL571
89 Samples
Download data: CEL
Series
Accession:
GSE11903
ID:
200011903
5.

Guselkumab (interleukin-23-specific monoclonal antibody) demonstrates clinical and molecular response in moderate-to-severe psoriasis

(Submitter supplied) A gene expression profiling study was conducted in which skin biopsy samples were collected for RNA extraction and hybridization to microarrays from patients with moderate-to-severe psoriasis who participated in the phase 1, guselkumab first-in-human randomized, double-blind, placebo-controlled trial. At week 12, significant reductions in psoriasis gene expression were observed in guselkumab-treated patients.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL13158
59 Samples
Download data: CEL
Series
Accession:
GSE51440
ID:
200051440
6.

Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis

(Submitter supplied) We sought to provide a comprehensive evaluation of the effects of TNF-α and IL-17 on the keratinocyte gene profile in order to identify genes that might be co-regulated by these cytokines. We then sought to determine how genes that were synergistically activated by both cytokines relate to the psoriasis transcriptome. Here, we identified 160 unique genes that were synergistically up-regulated by IL-17 and TNF-α and 188 unique genes where the two cytokines had at least an additive effect. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL6947
22 Samples
Download data: TXT
Series
Accession:
GSE24767
ID:
200024767
7.

IL-17A is an essential cytokine to sustain pathogenic cell activation and inflammatory gene circuits in psoriasis vulgaris

(Submitter supplied) In psoriasis, inflammation and epidermal hyperplasia are thought to be controlled by T cell-derived cytokines. Evidence now suggests that Th17 and Th22 cells infiltrate psoriasis lesions and by secreting IL-17 and IL-22, respectively, may drive disease-specific gene or cell responses. While studies in model systems indicate that IL-22 has a dominant pathogenic role, there is evolving evidence that IL-17 contributes to features of psoriasis. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS4458
Platform:
GPL571
30 Samples
Download data: CEL
Series
Accession:
GSE31652
ID:
200031652
8.
Full record GDS4458

Anti-IL-17 monclonal antibody ixekizumab effect on chronic psoriasis

Analysis of psoriatic skin biopsies from patients treated with 150mg of subcutaneous anti-IL-17 mAb ixekizumab (previously LY2439821) at weeks 0 and 2. IL-17 blockade resulted in a high-grade clinical improvement in psoriasis. Results provide insight into the role of IL-17 in disease pathogenesis.
Organism:
Homo sapiens
Type:
Expression profiling by array, transformed count, 2 agent, 17 individual, 2 time sets
Platform:
GPL571
Series:
GSE31652
30 Samples
Download data: CEL
9.

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways

(Submitter supplied) In this study, we shought to identify the cytokines produced by skin-resident T cells in normal skin, localize the receptors for these cytokines, and examine how these cytokines alter gene expression profiles of the cells bearing cognate receptors. Keywords: repeated measures experiment
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL571
12 Samples
Download data: CEL
Series
Accession:
GSE12109
ID:
200012109
10.

Type I Interferon: Potential Therapeutic Target for Psoriasis?

(Submitter supplied) We observed robust overexpression of type I interferon (IFN)–inducible genes and genomic signatures that indicate T cell and dendritic cell infiltration in lesional skin. Up-regulation of mRNAs for IFN-a subtypes was observed in lesional skin compared with nonlesional skin. Enrichment of mature dendritic cells and 2 type I IFN–inducible proteins, STAT1 and ISG15, were observed in the majority of lesional skin biopsies. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Dataset:
GDS3539
Platform:
GPL570
82 Samples
Download data: CEL
Series
Accession:
GSE14905
ID:
200014905
11.
Full record GDS3539

Psoriasis

Analysis of lesional and non-lesional skins from patients with psoriasis. Psoriasis is an immune-mediated disease characterized by aberrant epidermal differentiation, surface scale formation, and marked cutaneous inflammation. Results provide insight into the molecular pathogenesis of psoriasis.
Organism:
Homo sapiens
Type:
Expression profiling by array, transformed count, 2 disease state, 54 individual, 3 specimen sets
Platform:
GPL570
Series:
GSE14905
82 Samples
Download data: CEL
12.

Pathologic Immune Pathways in Psoriasis are Rapidly Attenuated by Tofacitinib Treatment: A Randomized Phase 2 Study in Patients with Moderate to Severe Psoriasis

(Submitter supplied) Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis. We sought to elucidate the molecular mechanisms underlying the clinical efficacy of tofacitinib in patients with psoriasis. Twelve patients with plaque psoriasis were randomized (3:1) to receive 10 mg of tofacitinib or placebo twice daily for 12 weeks. Biopsy specimens were taken from nonlesional (baseline) and lesional (baseline, days 1 and 3, and weeks 1, 2, 4, and 12) skin. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
95 Samples
Download data: CEL
Series
Accession:
GSE69967
ID:
200069967
13.

Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis

(Submitter supplied) The interleukin (IL)-23/T-helper type 17 cell axis is a target for psoriasis. The tyrosine kinase 2 (TYK2)/Janus kinase 1 (JAK1) inhibitor, PF 06700841, will directly suppress TYK2-dependent IL-12 and IL-23 signaling and JAK1-dependent signaling in cells expressing these signaling molecules, including T cells and keratinocytes. This clinical study sought to define the inflammatory gene and cellular pathways through which PF 06700841 improves the clinical manifestations of psoriasis. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
105 Samples
Download data: CEL
Series
Accession:
GSE136757
ID:
200136757
14.

Molecular and cellular profilling of scalp psoriasis reveals differences and similarities compared to skin psoriasis

(Submitter supplied) Scalp psoriasis shows a variable clinical spectrum and in many cases poses a great therapeutic challenge. However, it remains unknown whether the immune response of scalp psoriasis differs from understood pathomechanisms of psoriasis on other skin areas. We sought to determine the cellular and mollecular phenotype of scalp psoriasis by performing a comparative analysis of scalp vs skin using lesional and nonlesional samples from 20 Caucasian subjects with untreated moderate to severe psoriasis and significant scalp involvement, and 10 control subjects without psoriasis. more...
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL571
45 Samples
Download data: CEL
Series
Accession:
GSE75343
ID:
200075343
15.

Comprehensive transcriptome anaylsis of psoriasis in a Han Chinese population

(Submitter supplied) Psoriasis is a chronic inflammatory skin disease related to immune, whose complexity of molecular mechanisms is still not fully clear. RNA sequencing has been widely applied in various fields including biological medicine. According to the bioinformatics analysis of differential genes, biomarkers and drug targets have been discovered for the diagnosis and treatment of diseases. Besides, the pathological mechanisms of disease and functions of gene can be evaluated. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL17303
27 Samples
Download data: TXT
Series
Accession:
GSE114286
ID:
200114286
16.

Transcriptional Landscape of Psoriasis Identifies the Involvement of IL36 and IL36RN

(Submitter supplied) Background: In present study we performed whole transcriptome analysis in plaque psoriasis patients and compared lesional skin with non-lesional skin and with the skin from healthy controls. We sequenced total RNA from 12 lesional (LP), 12 non-lesional (NLP) and from 12 normal (C) skin biopsies. Results: Compared with previous gene expression profiling studies we had three groups under analysis - LP, NLP and C. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL16288
36 Samples
Download data: TXT
Series
Accession:
GSE66511
ID:
200066511
17.

RNA-seq identifies a diminished differentiation gene signature in primary monolayer keratinocytes grown from lesional and uninvolved psoriatic skin

(Submitter supplied) Keratinocyte (KC) hyper-proliferation and epidermal thickening are characteristic features of psoriasis lesions, but the specific contributions of KCs to plaque formation are not fully understood. This study used RNA-seq to investigate the transcriptome of primary monolayer KC cultures grown from lesional (PP) and non-lesional (PN) biopsies of psoriasis patients and control subjects (NN). Whole skin biopsies from the same subjects were evaluated concurrently. more...
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL10999
24 Samples
Download data: TXT
Series
Accession:
GSE107871
ID:
200107871
18.

RNAseq of IL-36 stimulated primary human keratinocytes

(Submitter supplied) Keratinocytes isolated from one healthy donor were stimulated in triplicate for 24h with IL-36α, IL-36β or IL-36γ
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL21290
12 Samples
Download data: TSV
Series
Accession:
GSE96601
ID:
200096601
19.

The spectrum of mild-to-severe psoriasis vulgaris is defined by a common activation of IL-17 pathway genes, but with key differences in immune regulatory genes

(Submitter supplied) Mild vs. severe psoriasis vulgaris is often distinguished by the Psoriasis Area and Severity Index. It is widely assumed that severe psoriasis involves higher levels of skin inflammation, but comparative molecular profiles of mild vs. severe disease have not been previously performed. In this study, we used gene arrays to phenotype North American patients with mild psoriasis vs. severe psoriasis.
Organism:
Homo sapiens
Type:
Expression profiling by array
Platform:
GPL570
33 Samples
Download data: CEL
Series
Accession:
GSE78097
ID:
200078097
20.

Transcriptomic studies to characterize the gene expression landscape of psoriasis

(Submitter supplied) This SuperSeries is composed of the SubSeries listed below.
Organism:
Homo sapiens
Type:
Expression profiling by high throughput sequencing
Platform:
GPL9052
216 Samples
Download data
Series
Accession:
GSE63980
ID:
200063980
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

db=gds|term=|query=1|qty=2|blobid=MCID_6169e9e962396b657042d6e0|ismultiple=true|min_list=5|max_list=20|def_tree=20|def_list=|def_view=|url=/Taxonomy/backend/subset.cgi?|trace_url=/stat?
   Taxonomic Groups  [List]
Tree placeholder
    Top Organisms  [Tree]

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center